These new data demonstrated that 'super responders'a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score
(C) 2022 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
149.3 USD | -0.43% | +2.14% | -4.77% |
May. 03 | Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate | MT |
May. 03 | J&J: to present advances in retinal diseases | CF |
These new data demonstrated that 'super responders'a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score
(C) 2022 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-4.77% | 359B | |
+21.85% | 546B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B | |
+1.72% | 123B |